About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, August 27th, 2013

The QualityStocks
Daily Stock List

graphic
graphic

International Isotopes, Inc. (INIS)

SmallCapVoice reported previously on International Isotopes, Inc. (INIS), and we report on the Company today, here at the QualityStocks Daily Newsletter.

International Isotopes, Inc. manufactures a full spectrum of nuclear medicine calibration and reference standards, high purity fluoride gases, and an assortment of cobalt-60 products such as teletherapy sources. They also provide a broad choice of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications. Additionally, they provide a host of analytical, measurement, recycling, and processing services on a contract basis to clients.

The Company has developed a unique process to convert depleted uranium tails (the by-product produced from the enrichment of uranium) to ultra-high purity, high value industrial fluoride products. Fluoride products are a key raw material for microelectronics, fiber optic cable, thin film photovoltaics (solar cells) and many other manufacturing processes. International Isotopes exclusively owns the patents for the fluorine extraction process and is planning to construct the first commercial depleted uranium de-conversion and fluorine extraction processing facility in the U.S.

International Isotopes' has their planned environmentally friendly, green technology, uranium de-conversion and fluorine extraction processing facility located near Hobbs, New Mexico. The new facility will be on a 640-acre site. The Company believes this new commercial facility will provide an excellent commercial opportunity. International Isotopes holds patents that give them exclusive rights for the Fluorine Extraction Process (FEP). This process produces high value, high purity fluoride gasses in tandem with uranium de-conversion.

The Company has their first de-conversion Service Agreement already in place with URENCO USA. URENCO is the leader in U.S. commercial enrichment. The International Isotopes business consists of five major business segments which include the Depleted Uranium De-Conversion and Fluorine Extraction Process (FEP) Project; Radiochemicals for Cancer Treatment; Nuclear Medicine Reference and Calibration Standards; Medical Teletherapy Products, and Transportation Services.

In October 2012, International Isotopes announced that they received a license from the U.S. Nuclear Regulatory Commission (NRC) to build a depleted uranium de-conversion and fluorine extraction processing facility. The license, which has a 40-year term, was signed October 2, 2012 by the NRC. The plant will use a two-step process to extract fluorine from depleted uranium. This is for use in solar materials, microelectronics, and the petrochemical markets.

This month, International Isotopes announced financial results for the second quarter and six-months ended June 30, 2013. Revenue for the three months ended June 30, 2013 was $1,800,049, in comparison to $2,042,949 for the same period the year prior. This represents an overall decrease of $242,900, or approximately 12 percent.  Revenue for the six-month period ended June 30, 2013, was $3,472,838, versus $3,992,292 for the same period a year ago. This represents a decrease of $519,454, or approximately 13 percent.

The Company’s net loss for the three months ended June 30, 2013 was $399,210. This is in comparison to $515,132 for the same period in 2012.  This is a decrease in net loss of $115,922, or approximately 23 percent. Their net loss for the six-month period ended June 30, 2013, was $1,068,102 versus $1,105,379 for the same period a year ago.  This is a decrease in net loss of $37,277, or approximately 3 percent.

International Isotopes, Inc. (INIS), closed Tuesday's trading session at $0.115, down 11.54%, on 16,765 volume with 3 trades. The average volume for the last 60 days is 32,555 and the stock's 52-week low/high is $0.061/$0.215.

Xun Energy, Inc. (XNRG)

PennyStocks24, DrStockPick, PennyOmega, BestOtc, CRWEFinance, PennyToBuck, StockHotTips, and CRWEWallStreet reported earlier on Xun Energy, Inc. (XNRG), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Xun Energy, Inc. is a development stage oil operating company. Their principal assets are in Venango County, Pennsylvania. The Company and their subsidiaries mainly engage in the acquisition of producing or near producing oil and gas properties and the development of these oil and gas properties. The Company’s projects will be conditional on completing their financing and the success of the drilling and completions program.

Xun Energy has their headquarters in Portland, Oregon. Incorporated on December 20, 2007 in the State of Nevada, the Company’s shares trade on the OTCQB. The Company was previously known as Real Value Estates, Inc. They changed their name to Xun Energy, Inc. in July of 2010.

This past June, Xun Energy announced that the Company's operator, Vencedor Energy Partners (VEP), completed the second and third oil well pad for the Company's five oil well drilling and completions program on the Rice Lease in Venango County, Pennsylvania.

Today, Xun Energy announced that Vencedor Energy Partners (VEP), completed the drilling, casing and cementing of their first oil well of a 30 well drilling program. Rice oil well number 15 was drilled to the Target Depth of 1,050' on the Rice lease, in Venango County, on August 26, 2013. Samples were taken during the drilling program for analysis.

Petroleum odors were emitted at the 720', 745', and 915' levels of the wellbore; this indicates oil presence at these depths. Xun Energy will not start drilling on the remaining four oil well locations on the Rice lease until after they complete their assessment of the first well.

Mr. Jerry G. Mikolajczyk, President and Chief Executive Officer of Xun Energy stated, "We are excited to have completed the drilling of our first oil well and the showings of petroleum odors are very encouraging and positive. This is the first step of a 3 step process before the oil well produces oil. This is a monumental accomplishment for us and our next step to generating revenues."

Xun Energy, Inc. (XNRG), closed Tuesday's trading session at $0.0014, up 27.27%, on 21,898,553 volume with 83 trades. The average volume for the last 60 days is 2,754,551 and the stock's 52-week low/high is $0.001/$0.05.

Nutra Pharma Corp. (NPHC)

PennyStocks24 and Winston Small Cap reported recently on Nutra Pharma Corp. (NPHC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Based in Coral Springs, Florida, Nutra Pharma Corp. operates as a biotechnology company. They market a number of drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. The Company, via their subsidiaries, carries out basic drug discovery research and clinical development. In addition, they seek strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma’s shares trade on the OTCQB.

Nutra Pharma specializes in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. These include Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.

The Nutra Pharma holding that acts as the drug discovery arm for the Company is ReceptoPharm. ReceptoPharm is developing proprietary therapeutic protein products mainly for the prevention and treatment of viral and neurological diseases in humans.

The wholly-owned medical devices subsidiary of Nutra Pharma is Designer Diagnostics. The Company engages in the marketing and sales of rapid diagnostics test kits for infectious diseases, including Tuberculosis and NonTuberculous Mycobacteria (NTM).

Nutra Pharma’s Nyloxin™ is an over-the-counter (OTC) pain reliever for the treatment of moderate to severe chronic pain. It is available as an oral spray and as a topical gel. Cobroxin® is the first over-the-counter pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug will be available as an oral spray and as a topical gel.

Last week, Nutra Pharma provided an update on the Company’s efforts to register their Nyloxin™ line of pain relievers with U.S. Governmental agencies. In December 2012, Nutra Pharma announced that they were introducing a stronger version of their OTC pain reliever, Nyloxin™, to be called Nyloxin™ Military Strength. The Company is registering the Nyloxin™ Military Strength and Nyloxin™ and Nyloxin™ Extra Strength with U.S. government agencies that will permit the eventual sales and distribution of these products into the active military, U.S. military base stores, as well as foreign embassies.

Nutra Pharma also announced that they initiated the process of registering their homeopathic treatment for chronic pain, Nyloxin™, in the country of South Africa. Moreover, the Company recently reported their issuance of Trademarks for Cobroxin® in Colombia and India. They also reported patents for the use of cobra venom in the treatment of pain that have been issued in the U.S. and India.

Nutra Pharma Corp. (NPHC), closed Tuesday's trading session at $0.0221, up 84.17%, on 33,745,418 volume with 513 trades. The average volume for the last 60 days is 3,428,633 and the stock's 52-week low/high is $0.0035/$0.0445.

Vasomedical, Inc. (VASO)

FeedBlitz reported earlier on Vasomedical, Inc. (VASO), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Founded in 1987, Vasomedical is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products.  The Company is a worldwide leader in non-invasive healthcare solutions and products. Vasomedical’s proprietary core product line of Enhanced External Counterpulsation (EECP®) Therapy systems is the leading product in the non-invasive treatment of cardiovascular disease. Vasomedical, headquartered in Westbury, New York, lists on the OTC Markets’ OTCQB.

Vasomedical operates through three wholly owned subsidiaries. These three are VasoSolutions, Vasomedical Global, and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture, and sales of EECP® Therapy systems, and other medical equipment operations. Vasomedical Global operates the Company's China-based subsidiaries. VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in particular markets.

EECP® Therapy is a non-invasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases. It is presently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs. It also decreases the heart’s workload and need for oxygen, while additionally improving function of the endothelium, the inner lining of blood vessels throughout the body, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, and improve the quality of life for thousands of people globally.

Earlier this month, Vasomedical reported their operating results for the three months ended June 30, 2013. Revenue increased 3 percent to $7.9 million from $7.7 million for the three months ended June 30, 2012. Gross profit for the second quarter of 2013 was $5.4 million, versus a gross profit of $5.5 million for the second quarter the year prior. Net loss for the three months ended June 30, 2013 was $537,000, or $0.00 per basic and diluted common share. This is in comparison to net income of $54,000, or $0.00 per basic and diluted common share, for the three months ended June 30, 2012. 

Recently, Vasomedical announced that that they will attend and exhibit at the 2013 European Society of Cardiology (ESC) Congress taking place from August 31 to September 3, 2013 in Amsterdam, The Netherlands. The ESC is the largest cardiology show in the world. Vasomedical will be in booth #A420, at the RAI Amsterdam Exhibition and Conference Centre. The Company will present their core technology, EECP Therapy, and their BIOX ECG Holter, ambulatory blood pressure monitors and patient management products. 

Vasomedical, Inc. (VASO), closed Tuesday's trading session at $0.289, even for the day, on 80,941 volume with 15 trades. The average volume for the last 60 days is 225,773 and the stock's 52-week low/high is $0.101/$0.37.

Skyline Medical, Inc. (SKLN)

SecretStockPromo reported yesterday on Skyline Medical, Inc. (SKLN), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 2002, and listed on the OTCQB, Skyline Medical, Inc. has a fully automated, patented, Food and Drug Administration (FDA) cleared, surgical fluid disposal system. This system essentially eliminates certain operating room workers' exposure to blood, irrigation fluid, and other potentially infectious fluids found in the surgical environment.

The Company previously went by the name BioDrain Medical, Inc. They changed their corporate name to Skyline Medical, Inc. this month. The Company has their headquarters in Eagan, Minnesota.

Skyline Medical's STREAMWAY System fully automates the collection, measurement, as well as disposal of surgical fluids. The design of this system is to result in reducing overhead costs to hospitals and surgical centers, improve Occupational State and Health Association (OSHA) and other regulatory compliance agencies' safety concerns, and streamline the efficiency and reduce the operating costs of the operating room.

The STREAMWAY System is eco-friendly; it contributes to cleaning up the environment. Presently, approximately 50 million bloody, potentially disease infected canisters go to landfills each year in the U.S. The number of canisters can be appreciably reduced, with the installation of the Company’s STREAMWAY System. Currently, Skyline Medical’s products are being represented via independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers nationwide.

With the STREAMWAY System, operative fluid is suctioned directly from the surgical field into the system. It automatically measures and records volume before it disposes of the fluid directly into a facility’s existing plumbing system. Cleaning the STREAMWAY System involves detaching the procedure filter, connecting the Company’s proprietary cleaning solution, and activating the cleaning cycle on the touch screen.

This month, Skyline Medical reported their results for the second quarter ended June 30, 2013. Revenues of $150,856 for Q2 2013 were up over 500 percent in comparison to Q2 2012 ($24,960). Year to date revenues rose to $278,583, versus revenues of $47,595 year to date in 2012. Gross profit for the second quarter of 2013 was $83,521. This represents an increase of over 250 percent, in comparison to $23,250 for the same period the year prior.
Skyline Medical’s net loss for the second quarter of 2013 was ($1.2) million, or ($0.01) per diluted share. This is in comparison to a net loss of ($2.1) million, or ($0.04) per diluted share, in the comparable period a year ago. The Company received more than 40 purchase orders in Q2 2013 for their new generation STREAMWAY FMS System, scheduled for delivery in Q3 and later.

Skyline Medical, Inc. (SKLN), closed Tuesday's trading session at $0.4199, up 39.97%, on 3,147,878 volume with 501 trades. The average volume for the last 60 days is 91,615 and the stock's 52-week low/high is $0.0501/$0.31.

Q4 Systems Corp. (QFOR)

Bullseyestox.com, AddictivePennyStocks, PennyStockRumors.net, Stock Legends, Actual Gains, PricelessPenny, and Orbit Stocks reported earlier on Q4 Systems Corp. (QFOR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Q4 Systems Corp. delivers end-to-end information technology solutions to their clients via a distinctive blend of technology platforms, consulting, and Information Technology (IT) services from the Company’s global delivery centers. Based in Rolling Meadows, Illinois, the Company is a foremost provider of Health Exchange platforms (QHIX) and proprietary set of SMAC (social media, mobility, analytics and cloud computing) technology solutions to enterprise clients in Financial Services, Health Care, Retail, and Manufacturing sectors. Q4 Systems’ shares trade on the OTC Markets’ OTCQB.

The Company has their development centers in in New Jersey, Illinois, and California. In addition, Q4 Systems operates satellite client centric development/support centers organized at client locations. Q4 offers software products, platforms, consulting services, and solutions covering proprietary technologies in social media, mobility, analytics, and cloud applications to small, medium, and large enterprise customers.

Q4 Systems’ business lines encompass Solutions, Consulting, Managed Services, and Technology. Solutions comprise ERP, Product Engineering Services, Application Management Outsourcing, Business Intelligence, and Custom Applications. Consulting consists of Architecture, API, Database Management, Testing, and System Integration.

Managed Services consist of Field Engineering, Hosting, BPO, and IT-in-a-Box. Technology consists of Bolt on Products, Frameworks, and Cloud Applications.

Today, Q4 Systems announced that the Company entered into a contract to develop a unique mobile application designed for the automobile industry. Q4Mobile, a unit of Q4 Systems, has commenced developing a state-of-the-art vehicle inspection application for their client, MyCustomerData (MCD). The marketing of this solution will be to thousands of car dealerships coast-to-coast. It is being rolled out at a number of luxury dealerships in Southern California.

Q4 Mobile specializes in front-line technologies relating to web, mobility, Big Data, NoSQL, Cloud Computing, Mobile App Development, Game Development, NFC, QR Code and Augmented Reality, Web and Mobile Commerce. Q4 Mobile enables industries, for example Retail, Healthcare, Automotive, Nonprofit, Library, Telematics and Telemetrics, to leverage technology to gain competitive advantage through significantly increasing efficiency, reach, as well as response rates.

Q4 Systems Corp. (QFOR), closed Tuesday's trading session at $0.25, down 28.57%, on 140,493 volume with 27 trades. The average volume for the last 60 days is 31,701 and the stock's 52-week low/high is $0.02/$0.45.

MMRGlobal, Inc. (MMRF)

SmallCapVoice, FeedBlitz, and PennyStocks24 reported earlier on MMRGlobal, Inc. (MMRF), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Based in Los Angeles, California, MMRGlobal, Inc., via their wholly owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records (PHRs) and MyEsafeDepositBox storage solutions. Additionally, they provide electronic document management and imaging systems for healthcare professionals. MMRGlobal announced earlier this year that the Company’s principal business would be expanded from their previous focus of selling consumer and professional products and services, to equally exploiting and licensing their health information technology patents nationally and worldwide. MMRGlobal lists on the OTC Markets’ OTCQB.

MMRGlobal serves consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. Through their merger with Favrille, Inc. in January of 2009, MMRGlobal acquired intellectual property (IP) biotech assets that include anti-CD20 antibodies and data and samples from their FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma.
   
The Company’s MyMedicalRecords PHR enables individuals and families to access their medical records and other vital documents anytime from anywhere using the Internet.  The building of MyMedicalRecords is on proprietary, patented technologies to allow documents, images and voicemail messages to undergo transmission and storage in the system using a variety of methods. This includes fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account.

MMRGlobal's professional offering is MMRPro. The design of MMRPro is to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients by way of an integrated patient portal.

Yesterday, MMRGlobal announced that due to the Expedited Patent Allowance Program referred to as the Patent Prosecution Highway (PPH), and following the issuance of U.S. patents to the Company for their anti-CD20 monoclonal antibodies, MMRGlobal received confirmation of the filings of a divisional application for their antibody technology in Japan, No. P09277JP01, and the filing on August 23, 2013 of a divisional Korean patent application, No. 10-2013-7022383. These filings are in addition to their recently announced filing of a divisional Chinese patent application, No. 200780051557.6, on August 15, 2013. 

MMRGlobal, Inc. (MMRF), closed Tuesday's trading session at $0.0335, down 6.69%, on 91,712 volume with 15 trades. The average volume for the last 60 days is 666,016 and the stock's 52-week low/high is $0.014/$0.125.

Dephasium Corp. (DPHS)

Ascending Stocks, Hot Stock Profits, Penny Stocks VIP, BestStocksDaily, HoleinOneStocks.net, Top Stock Tips, and PennyStocks24 reported recently on Dephasium Corp. (DPHS), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTC Markets’ OTCQB, Dephasium Corp. has acquired the U.S. Ancilia trademark and patent from Dephasium, Ltd. The Company's intention is the commercialization of that product. Dephasium plans to become the leader in the field of people protection against electromagnetic waves emitted by mobile phones. Founded in 2006, Dephasium has their U.S. headquarters in Miami, Florida.

Dephasium owns three registered patents. The Company is offering one product range currently- Ancilia protecting phone covers. Dephasium has completed the acquisition of the Ancilia patent and trademark, Registration Number 4,085,620 (the Assets). In return for the Assets, Dephasium issued to Dephasium, Ltd., a United Kingdom limited partnership, 70,000,000 shares of their restricted common stock. The Company valued the acquisition of the assets at $1.2 million.

Dephasium Ltd. has succeeded in developing an Ancilia product that they believe protects up to 98 percent of electromagnetic waves issued by cell phones. The foundation of this conclusion is upon the results of technology tests administered by Cetecom ICT Services and included in their written report dated August 10, 2009. Ancilia is a new range of smartphone cases providing this protection against electromagnetic waves, which is verified through the measurement of SAR reduction.

In early June, Dephasium announced that the Company has entered into an exclusive distribution agreement with Dephasium Ltd. to make and sell Dephasium Ltd.’s products in the U.S. and Canada. The agreement provides for a term of five years with successive five year renewals. With this Agreement, the Company will receive a fee equal to 30 percent of all sales in the U.S. and Canada.

In addition, in June, Dephasium announced in conjunction with Dephasium, Ltd., the opening of their online store, www.Dephasiumstore.com. The online store will enable the Company to sell the products that they are distributing in the U.S. and Canada in combination with the Company’s Distribution Agreement with Dephasium, Ltd.

Dephasium Corp. (DPHS), closed Tuesday's trading session at $0.0285, up 2.89%, on 384,508 volume with 20 trades. The average volume for the last 60 days is 1,014,778 and the stock's 52-week low/high is $0.022/$0.61.

graphic

The QualityStocks
Company Corner

graphic
graphic

Dragon Capital Group Corp. (DRGV)

The QualityStocks Daily Newsletter would like to spotlight Dragon Capital Group Corp. (DRGV). Today, Dragon Capital Group Corp. closed trading at $0.0025, up 38.89%, on 9,152,853 volume with 100 trades. The stock’s average daily volume over the past 60 days is 3,746,008 and its 52-week low/high is $0.0009/$0.01.

Dragon Capital Group Corp. announced today that its Shanghai Yazheng Information Technology subsidiary was picked by the Chinese Central Government as one of the participants in a national science and technology research project focusing on the application of safe, large-scale programmable logic controllers. Anticipated as kicking off Q4 this year and lasting through 2015, the project is estimated at a total R&D cost of roughly $3M to the government and represents a huge opportunity for DRGV to flex their muscle in PLCs.

Dragon Capital Group Corp. (DRGV) operates through its six subsidiaries in the People's Republic of China with a specific focus on the technology market. Serving as a conduit between Chinese high-growth companies and Western investors, the company provides support in the critical functions of general business consulting, formation of joint ventures, access to capital, merger & acquisition, business valuation, and revenue growth strategies.

The development of wireless applications and business solutions is a large area of focus. Two companies Dragon has acquired are among the leading providers of mobile applications and business software in China. Shanghai Zhaoli, one of these two companies, recently received a Ten Year Outstanding Contribution Award from HP to recognize the distinguished contribution made as HP's foreign authorized distributor in Greater China Region.

Through its subsidiaries, Dragon represents a wide array of name brand manufacturers, including Hewlett Packard, Epson, Canon, Ricoh, Brother, Star, and Samsung. Dragon’s seasoned professionals have experience with both the laws and business practices of China. This experience serves as a competitive advantage for Dragon’s portfolio companies.

Dragon aims to emerge as a significant force in the high-tech sector of China. Employing expertise of Chinese and U.S. business practices, Dragon is establishing a successful track record nurturing Chinese companies. The company’s unique combination of professionals represents a powerful resource critical to maintaining and accelerating its growth. Disclaimer

Dragon Capital Group Corp. Blog

Dragon Capital Group Corp. News:

Dragon Capital Group Subsidiary to Participate in National Science and Technology Research Project Focusing on Large Scale Programmable Logic Controllers

Dragon Capital Group Subsidiary Awarded Contract for Central Control System Upgrade at Huinan Waterworks Facilities

Shanghai City North Gas Company, Ltd. to Use Dragon Capital Group's Gas Information System for Gas Valve Grouping Project

Epazz Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz Inc. (EPAZ). Today, Epazz Inc. closed trading at $0.0012, up 20.00%, on 5,548,067 volume with 66 trades. The stock’s average daily volume over the past 60 days is 14,276,274 and its 52-week low/high is $0.0006/$0.0125.

Epazz, Inc. reminded long-term shareholders today that the record date for Project Flex Spin-off will be September 15, 2013 and that, in order to receive the stock dividend, shareholders need to have the share settled three days prior to the record date. Epazz, Inc.'s CEO, Shaun Passley, said, "This is our first spin-off, but not the last spin-off. Our business plan provides Long-term shareholders multiple opportunities for stock dividends. We believe transitioning Epazz to a holding company will provide long-term value."

Epazz Inc. (EPAZ) is a leading cloud-based software company focused on providing customized cloud applications to Fortune 500 enterprises, government agencies, and higher education institutions. Targeting a strong growth industry, the company is rapidly expanding via strategic acquisitions, a full suite of in-house products and services, and diversified streams of income.

The fully reporting company is demonstrating substantial performance in a competitive industry, completing six acquisitions while maintaining organic subsidiary growth. In the last three years, Epazz revenues have increased by more than 300%. The company will produce its first spinoff with “Project Flex” and issue a stock dividend to shareholders of record on the record date.

As an enterprise-wide software company, Epazz is adeptly serving the increasing information technology demand of the 21st century. According to IDC, the premiere global market intelligence firm, the IT cloud services industry is expected to grow from $40 billion to $100 billion in just four years. Management anticipates the company’s growth to accelerate as the market for its technology solutions continues to expand.

Epazz BoxesOS™ v3.0 is the complete business web-based software package for small to mid-size businesses, Fortune 500 enterprises, government agencies, and higher education institutions. The turnkey enterprise system, which includes content, integration, customization, and marketing services, provides many of the web-based applications organizations would have to otherwise buy separately. Disclaimer

Epazz Inc. Blog

Epazz Inc. News:

Epazz Stock Dividend Reminder: Project Flex Spin-Off Record Date Set for September 15, 2013

Epazz Client Base Grows Over 500% in 3 Years

Epazz Advances Project Human Mobile Power Spinoff

OxySure Systems, Inc. (OXYS)

The QualityStocks Daily Newsletter would like to spotlight OxySure® Systems, Inc. (OXYS). Today, OxySure Systems, Inc. closed trading at $0.83, up 10.67%, on 12,420 volume with 10 trades. The stock’s average daily volume over the past 60 days is 6,844, and its 52-week low/high is $0.35/$2.75.

OxySure Systems, Inc. was reiterated today with a Speculative Buy rating from analysts at full service brokerage firm specializing in the microcap segment, Taglich Brothers, with a 12-month price target of $2.10 on the stock. In the research update, Taglich Brothers also raised its revenue estimates for OXYS in anticipation of higher sales from the company's military subcontract. The research firm expects sales to rise from $2 million in 2013 to $4.9 million in 2015. By 2017, revenues are projected to increase to $18 million.

OxySure Systems, Inc. (OXYS) is a medical technology company focused on developing, manufacturing, and distributing specialty respiratory and medical solutions. The company has developed a unique platform technology that instantly creates medically pure oxygen from two dry, inert powders, allowing oxygen to be delivered on demand. This cutting-edge technology has already been granted FDA-approved for commercial sale.

The company is targeting multiple enormous end markets with no direct competition. OxySure initially plans to focus on the 102,265 educational campuses, 350,735 manufacturing facilities, 350,000 churches, 12 million recreational vehicles (RVs), 8 million boats and yachts, 950,000 restaurants, and hundreds of thousands of other commercial and municipality facilities in the U.S. Outside the US, OxySure has also already signed significant distribution agreements, including Australia, New Zeeland, the United Kingdom, the Netherlands, Luxembourg, Belgium, Brazil, and South Africa. OxySure’s potential market is at least as large as AEDs and potentially as large as fire extinguishers, which together total at least 500+ million units worldwide.

OxySure’s flagship product, OxySure Model 615, introduces the first new oxygen technology in 50 years. There are no compressed tanks, no dials, no valves, no regulatory maintenance, no hydrostatic testing, no batteries, and no required training, and the technology is both safe and easy-to-use for the layperson. It can be placed virtually anywhere to help save lives by bridging the gap between a medical emergency and the arrival of first responders on the scene.

The company aims to capitalize on market opportunities primarily through partnerships with distributors and OEM customers. Protected by numerous issued patents and patents pending, the company’s products are available over-the-counter without the need for a prescription and has already saved thousands of lives around the globe during various types of medical emergencies. Disclaimer

OxySure Systems, Inc. Company Blog

OxySure Systems, Inc. News:

Taglich Brothers Reiterates Speculative Buy Rating on OxySure Systems, Inc.

OxySure Systems, Inc. CEO Featured in Exclusive QualityStocks Interview

OxySure Systems Reports Second Quarter 2013 Results

On the Move Systems, Inc. (OMVS)

The QualityStocks Daily Newsletter would like to spotlight On the Move Systems, Inc. (OMVS). Today, On the Move Systems, Inc. closed trading at $0.28, on 428,761 volume with 146 trades. The stock’s average daily volume over the past 60 days is 63,619, and its 52-week low/high is $0.0027/$0.37.

On The Move Systems Corp. reported today that they met last week with a charter airline service that the company has targeted for potential partnership or acquisition, all as part of the company's continued mission to provide niche transportation options to online customers. Development has already begun alongside ByterDyne to deliver a new innovation known as the ISTx platform, the digital heart of an online portal designed to connect users with discounted transportation options from charter jet service to luxury ground shuttles and beyond, a portal which stands to put OMVS on a footing with big players like Priceline and Expedia.

On the Move Systems, Inc. (OMVS) has established a scalable business model for leveraging the available routes and “legs” of private aviation to book private air charter, freight, and animal/exotic transport services. Their unique ISTx software is designed for managing and supporting services and routes across multiple private/commercial carriers through this single platform.

Management places strong emphasis on customer satisfaction and approaches this viewpoint by creating a unique flight or service profile for each client. The company has developed a business model offering this profile access through various proprietary and membership models. Additionally, its business strategy incorporates acquiring or joining with smaller charter plane owners. The company has further established various divisions which address particular client needs and routes. Leveraging its unique business model with a host of innovative solutions for expanding markets, OMVS is well positioned for rapid growth.

Current divisions of OMVS include Charter Services, Inter-Modal Freight, and Animal/Exotic Transport. The Charter Services Division offers private charter airplane owners the opportunity to enter a network where available planes will be "on-call" to deliver private air charter service on demand. The Inter-Modal Freight Division provides charter and freight shipping services to clients who need to expedite shipment of cargo and freight globally – including medical transport for tissue and isotopes. The company's Animal/Exotic Transport Division affords clients the security of transporting pets and animals without the accompaniment of the owner.

OMVS continues to develop technology and applications that connect all business touch points - passengers, assets, and routes. The company intends to monitor daily operations through a single platform providing ultimate support for all business activities. OMVS is in the final stages of development with the ISTx platform and plans to implement system wide in the next two fiscal quarters. Disclaimer

On the Move Systems, Inc. Company Blog

On the Move Systems, Inc. News:

OMVS Opens Talks With Potential Air Charter Acquisition

OMVS Proceeds with Development of Groundbreaking Transportation Portal

OMVS Lines Up New Acquisition Targets in $300 Billion Online Transportation Industry

Dragon Capital Group Corp. (DRGV) Subsidiary Chosen to Participate in National Science and Technology Research Project

Dragon Capital Group, a leading holding company of emerging high-tech companies in China, today announced that its Shanghai Yazheng Information Technology Company (“Yazheng”) subsidiary has been selected by the Chinese Central Government as one of the participants in a national science and technology research project focusing on the application of safe and large-scale programmable logic controllers (PLC’s). With a total estimated R&D cost of approximately 20 million RMB ($3 million U.S.), this project is expected to begin in the fourth quarter of 2013 and last through 2015.

As China continues to accelerate the process of industrialization and automation, more and more companies are attempting to expand the scale of production. Productions facilities with multiple parameters, high risk and full automation features are being deployed across a wide array of industries including energy, transportation, manufacturing, aerospace, and chemical production. As a result, market demand for high-end safety control products is growing rapidly throughout China.

The current overall PLC market is estimated to be approximately 6-7 million RMB annually with the market for large-scale PLC’s including large industrial plant control systems, safety interlock systems, safety instrumented systems, and high-end security control systems representing about 30% or 2 billion RMB. This market, which is expected to experience a better than 10% annual growth rate, has been mainly dominated by large foreign corporations. Projects like this are being sponsored by the government to foster domestic development of high-end control systems to enable China based companies to capture a much larger percentage of this fast growing market. The participants in this project will be able to utilize technologies developed through this government assistance to design practical applications for future commercialization.

Mr. Lawrence Wang, Chairman and CEO of Dragon Capital Group, stated, “We are very pleased to have been selected by the Central Government for this project as a result of our automation work in the utility industry. With the government essentially subsidizing the R&D efforts of the participants, we have the unique opportunity to enter large scale markets in the future. This will also help us add further functionality to our current monitoring systems as we continue to deploy and gain market share. We will continue to support Yazheng in their efforts to build this important business segment for the future growth of Dragon Capital.”

For additional information, visit www.DragonCapital.us

Epazz, Inc. (EPAZ) Issues Dividend Reminder to Investors; Record Date Set for September 15, 2013

Epazz, a leading provider of cloud based business software solutions, today reminded long-term shareholders that the record date for Project Flex Spin-off will be September 15, 2013. In order to receive the stock dividend, investors must have shares settle three days prior to the record date.

The company emphasized that only shareholders of record date will receive the 1-10 stock dividend announced earlier. The spin-off of Project Flex will be above $0.01 per share. For each 10 shares of EPAZ common stock that a shareholder owns, the shareholder will receive 1 share of stock in the new Project Flex spinoff.

Shaun Passley, Epazz CEO, said, “This is our first spin-off, but not the last spin-off. Our business plan provides Long-term shareholders multiple opportunities for stock dividends. We believe transitioning Epazz to a holding company will provide long-term value.”

Epazz is a leading cloud based software company that specializes in providing customized cloud applications to the corporate world, higher education institutions, and the public sector. The company’s BoxesOS(TM) v3.0 is the complete business web-based software package for small to mid-size businesses, Fortune 500 enterprises, government agencies, and higher education institutions. BoxesOS provides many of the web-based applications organizations would have to otherwise buy separately. Epazz’s other products are DeskFlex (TM), a room scheduling software, and AutoHire(TM), an applicant tracking system.

For more information, visit www.epazz.com

Taglich Brothers Reiterates Buy Rating on OxySure Systems, Inc. (OXYS); Target Price $2.10 Per Share

OxySure Systems, a medical technology company that has pioneered an FDA-approved solution to produce medically pure oxygen from dry, inert powders for emergency/short duration use, was reiterated with a Speculative Buy rating from analysts at Taglich Brothers. Taglich Brothers set a 12-month price target of $2.10 on the stock.

In the research update, Taglich Brothers also raised its revenue estimates for OXYS in anticipation of higher sales partially attributable to the company’s military business. The research firm expects sales to rise from $2 million in 2013 to $4.9 million in 2015. By 2017, revenues are projected to increase to $18 million.

To see the 15-page report in its entirety, follow the link posted under additional resources at http://dtg.fm/oxys.

On the Move Systems, Inc. (OMVS) Sees Potential Air Charter Acquisition as Supporting Catalyst into Explosive Online Travel Industry

On the Move Systems, in line with its mission to provide niche transportation options to online customers, last week met with an undisclosed charter airline service to discuss potential partnership or acquisition opportunities.

The target is a Texas-based carrier that for more than 10 years has provided same-day passenger and air cargo services at affordable prices, curbing the challenges and frustrations in boarding and unreliable scheduling often associated with major airlines.

OMVS sees significant opportunity in acquiring the niche services of a private airline with a charter license and combining it with OMVS’ groundbreaking ISTx software platform. By pairing these variables, the company believes it will have a unique position in the $300 billion online travel industry.

As such, OMVS sees the Texas-based carrier as an ideal potential acquisition target, through which it could take advantage of the growing demand for private air service, contributing to OMVS’ aggressive plans to revolutionize commercial travel and transportation booking in the United States.

In correlation with this overarching plan, OMVS is developing its new online transportation portal designed to deliver more travel options to business and consumers, and recently signed a development partnership agreement with ByterDyne, an designer of scalable, custom software solutions for the energy, transportation/logistics, and e-commerce industries.

Together, the companies are developing the innovative ISTx platform, the core of an online portal designed to connect users with discounted transportation options from charter jet service to luxury ground shuttles and beyond.

For more information, visit www.onthemovesystems.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Top Stock Tips
(BMMCF)

2.

Winston Small Cap
(NPHC)

3.

Real Pennies
(DANR)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251